Publication | Closed Access
Systemic candidiasis in very low-birth-weight infants (less than 1,500 grams).
174
Citations
11
References
1984
Year
NeonatologyClinical MycologyPremature InfantsHealthcare-associated InfectionSystemic CandidiasisVaginitisSepsisAmphotericin BInfection ControlAntimicrobial ResistanceAntifungal AgentsMaternal HealthNewborn MedicineClinical MicrobiologyAntifungal AgentAntibioticsCandida AlbicansPediatricsMedicine
Previous reports in the literature have documented that systemic infection with Candida albicans in very premature infants is frequently fatal (54%) or associated with significant morbidity in survivors (25%). Five patients with a mean birth weight of 829 g had a diagnosis of systemic candidiasis during their stay in a newborn intensive care unit. All infants survived with minimal sequelae following aggressive early treatment with amphotericin B and 5-flucytosine. A review of these five extremely premature infants and 26 previously reported patients suggests the following: (1) disseminated candidiasis is common in the absence of positive findings in blood, CSF, and/or urine cultures; (2) transient candidemia rarely resolves without therapy; (3) meningitis and osteoarthritis occur more frequently than in older patients with disseminated disease; and (4) premature infants tolerate amphotericin B and 5-flucytosine well. Infants who are found to have systemic cultures positive for candidiasis should be treated by (1) removing all factors that predispose to systemic candidiasis (eg, indwelling catheters, broad-spectrum antibiotics); (2) early initiation of systemic antifungal therapy with amphotericin B and 5-flucytosine; and (3) searching for additional foci of disease. After the disease is recognized and treatment is prompt and aggressive, outcome can be substantially improved.
| Year | Citations | |
|---|---|---|
Page 1
Page 1